Oral Ibrexafungerp outcomes by fungal disease in patients from an interim analysis of a Phase 3 Open-label Study (FURI)

Jürgen Prattes; T King; N Azie; D Angulo

doi:10.1093/mmy/myac072.P056

Oral Ibrexafungerp outcomes by fungal disease in patients from an interim analysis of a Phase 3 Open-label Study (FURI)

Jürgen Prattes
, T King
, N Azie
, D Angulo

Klinische Abteilung für Infektiologie

Publikation: Beitrag in Fachzeitschrift › Konferenzabstract

10 Quellenangaben (Web of Science)

Originalsprache	Englisch
Fachzeitschrift	Medical Mycology
DOIs	https://doi.org/10.1093/mmy/myac072.P056
Publikationsstatus	Veröffentlicht - 2022
Veranstaltung	ISHAM 2022: 21st Congress of the International Society for Human and Animal Mycology - New Delhi, Indien Dauer: 20 Sep. 2022 → 24 Sep. 2022

Wissenschaftszweige

302 Klinische Medizin
305 Andere Humanmedizin, Gesundheitswissenschaften

Zugriff auf Dokument

10.1093/mmy/myac072.P056

Andere Dateien und Links

Web of Science

Oral Ibrexafungerp outcomes by fungal disease in patients from an interim analysis of a Phase 3 Open-label Study (FURI)
Prattes, J. (Autor*in), King, T. (Autor*in), Azie, N. (Autor*in) & Angulo, D. (Autor*in)
2022
Aktivität: Vortrag oder Poster › Poster

Dieses zitieren

@article{5765ecea719842329bde84ab5e835000,

title = "Oral Ibrexafungerp outcomes by fungal disease in patients from an interim analysis of a Phase 3 Open-label Study (FURI)",

author = "J{\"u}rgen Prattes and T King and N Azie and D Angulo",

year = "2022",

doi = "10.1093/mmy/myac072.P056",

language = "English",

journal = "Medical Mycology",

issn = "1369-3786",

publisher = "Oxford University Press",

note = "ISHAM 2022: 21st Congress of the International Society for Human and Animal Mycology ; Conference date: 20-09-2022 Through 24-09-2022",

}

TY - JOUR

T1 - Oral Ibrexafungerp outcomes by fungal disease in patients from an interim analysis of a Phase 3 Open-label Study (FURI)

AU - Prattes, Jürgen

AU - King, T

AU - Azie, N

AU - Angulo, D

PY - 2022

Y1 - 2022

UR - https://www.webofscience.com/wos/woscc/full-record/WOS:000868689700156

U2 - 10.1093/mmy/myac072.P056

DO - 10.1093/mmy/myac072.P056

M3 - Conference abstract

SN - 1369-3786

JO - Medical Mycology

JF - Medical Mycology

T2 - ISHAM 2022: 21st Congress of the International Society for Human and Animal Mycology

Y2 - 20 September 2022 through 24 September 2022

ER -

Oral Ibrexafungerp outcomes by fungal disease in patients from an interim analysis of a Phase 3 Open-label Study (FURI)

Wissenschaftszweige

Zugriff auf Dokument

Andere Dateien und Links

Aktivitäten

Oral Ibrexafungerp outcomes by fungal disease in patients from an interim analysis of a Phase 3 Open-label Study (FURI)

Dieses zitieren